Business
OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting
OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General MeetingNew Board Structure Reflects Balanced and Proportionate Shareholder Representation New Governance to Drive Strategic Roadmaps for Tedopi® and Lusvertikimab Nantes, August 25, 2025, 7:00 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces the convening of its Annual General Shareholders’ Meeting, to be held on September 30, 2025, along with a proposed
About this update from Ose Immunotherapeutics Sa
[{"type":"image","alt":"OSE Immunotherapeutics","displaySize":"","headline":null,"caption":"OSE Immunotherapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/h55Oot7mWh39J7Yvj1GueA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb","width":300,"height":100}},"lazy":false},{"type":"text","content":"OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General MeetingNew Board Structure Reflects Balanced and Proportionate Shareholder Representation New Governance to Drive Strategic Roadmaps for Tedopi® and Lusvertikimab","length":277,"tagName":"p"},{"type":"text","content":"Nantes, August 25, 2025, 7:00 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces the convening of its Annual General Shareholders’ Meeting, to be held on September 30, 2025, along with a proposed evolution in its governance. This move reinforces the company’s commitment to balanced and proportionate shareholder representation and strategic alignment.","length":381,"tagName":"p"},{"type":"text","content":"The proposed governance framework is in the context of ongoing discussions with concertist shareholders. It aims to ensure international expertise, while maintaining independence and continuity to support the company’s two key therapeutic areas, and to explore all strategic options in the best interests of patients and all shareholders.","length":338,"tagName":"p"},{"type":"text","content":"New, adapted governance to support OSE’s strategic objectives ","length":61,"tagName":"p"},{"type":"text","content":"The proposed reshaped Board structure would comprise: two seats for current independent Board members; two for new independent directors, two for concertist shareholders (representing 20% of the shareholder equity); one for the CEO; and one for the representative of employee shareholders. As a consequence of this evolution, certain directors would step down or not renew their mandates. This reshaped Board is designed to reflect the diversity of its shareholder base and to prepare OSE for its next strategic opportunities and challenges.","length":541,...